Cumberland Pharmaceuticals Reports $77.8 Million Q3 Net Income, Plans DMD NDA

Cumberland Pharmaceuticals reported third-quarter 2026 net income of $77.8 million, including a gain on the disposal of discontinued operations, while continuing operations recorded a net loss of $1.1 million. The quarter was the company’s first full period following the July closing of its strateg…